Wegovy Pill vs Injection: Price, Results and Switching in Germany

Since 1 September 2026, German pharmacies have stocked Wegovy as a daily tablet, and the question patients now bring to their doctors is a practical one: Wegovy pill vs injection, which one makes more sense? A recent ARD GESUND report followed two women weighing exactly that choice. Vanessa, 37, had lost about 20 kg on Mounjaro but was vomiting several times a day. Monika, 44, has a needle phobia and had never considered an injection at all. Their reasons say a lot about how the two forms differ. In Germany, price has stopped being one of the differences.

Wegovy pill vs injection: the same drug through a different door

The tablet contains semaglutide, the same GLP-1 receptor agonist as the Wegovy pen. Vanessa's injection was a different drug: Mounjaro is tirzepatide, which also acts on a second receptor. Both semaglutide forms are prescription-only and approved for adults with a BMI of 30 or more, or 27 or more with a weight-related condition such as high blood pressure. The European Commission approved the tablet on 15 July 2026. Unlike the injection, which is approved from age 12, the tablet is for adults only.

The harder question is how a peptide survives the stomach at all. Normally, stomach acid activates pepsin, which cuts protein chains apart. The tablet adds an absorption enhancer called SNAC (salcaprozate sodium), which briefly raises the pH right around the tablet so the drug can cross the stomach lining before it is broken down.

It still works poorly by injection standards. According to the EU product information, about 89% of injected semaglutide reaches the bloodstream, against roughly 1 to 2% from the tablet. That gap explains the doses: the tablet's maintenance dose is 25 mg every day, while the pen delivers 2.4 mg once a week.

What the Wegovy pill costs in Germany

German trade press published the launch prices in late August, and the 25 mg maintenance tablet has since been listed as well. Neither form is covered by statutory health insurance for weight loss, so patients pay the full pharmacy price.

Prices per pack (30 tablets, or four weeks of pens):

• Starting doses cost €172.73 in both forms: 1.5 mg and 4 mg tablets, 0.25 to 1 mg pens.
• The step before maintenance is €233.23 for 9 mg tablets and €237.14 for 1.7 mg pens.
• The maintenance dose costs €277.60 in both forms: 25 mg tablets and 2.4 mg pens.
• Only the pen has a higher dose, 7.2 mg, at €383.80.

At maintenance, both packs cost the same. A tablet pack covers 30 days and a pen pack 28, so the tablet works out slightly cheaper per day: about €9.25 against €9.91. The ARD report put the monthly cost at roughly €170 to €280, depending on dose. Vanessa was paying €280 to €350 a month for Mounjaro, which is why she hoped the switch would save money.

The reason for the bill is a legal one. Section 34 of Germany's Social Code (SGB V) excludes drugs used to reduce weight or curb appetite from statutory cover, and the Federal Joint Committee (G-BA) lists Wegovy among them. In August 2026, G-BA chair Sonja Optendrenk called cover under certain conditions worth considering, while stressing that only lawmakers can change the rule. AOK's Carola Reimann countered with a figure of up to €45 billion a year if every insured adult with a BMI of 30 or more were treated, a number she herself called a maximum scenario. Nothing has changed so far. For how Germany treats other peptide products, see our guide to peptide legality in Germany.

Do the results match? OASIS 4 vs STEP 1

No trial has compared the tablet and the pen head to head, so the fair comparison is between each one's pivotal study, read the same way.

• OASIS 4 (NEJM, 2025) tested oral semaglutide 25 mg in 307 adults without diabetes for 64 weeks. Average weight loss was 13.6%, against 2.2% on placebo. About 28% of participants lost at least a fifth of their body weight.
• STEP 1 (NEJM, 2021) tested the 2.4 mg injection in 1,961 adults for 68 weeks. Average weight loss was 14.9%, against 2.4% on placebo.

The "about 17%" figure in some coverage of the tablet comes from a different analysis that assumes everyone stayed on treatment. It shouldn't be set beside STEP 1's 14.9%. The EU product information concludes that efficacy and safety were similar across the two programmes, regardless of route.

Side effects followed the familiar GLP-1 pattern. In OASIS 4, 46.6% of tablet users reported nausea and 30.9% vomiting, mostly while the dose was being raised, and 3.4% stopped because of stomach problems. Pharmacist Maren Torkler notes that nausea and vomiting are listed slightly more often for the tablet, diarrhoea and constipation slightly more often for the pen. The pen does keep one advantage: a 7.2 mg dose, which reached 18.7% average weight loss in the STEP UP trial. Our semaglutide vs tirzepatide comparison covers how both drugs stack up beyond the pill question.

The morning rule that decides whether the tablet works

Because so little semaglutide gets through the stomach, small mistakes cost a lot. The EU product information sets out the conditions for taking it:

• on an empty stomach, after at least eight hours without food;
• swallowed whole with up to half a glass of water (120 ml);
• followed by at least 30 minutes without food, other drinks or other oral medicines.

Food, larger amounts of water or a shorter wait all reduce absorption. The label also warns that absorption from the tablet varies a lot from person to person and can be minimal. Torkler adds a practical detail: the tablets draw moisture from the air, so they should stay in their blister until the moment they are taken, never in a weekly pill organiser.

Torkler also sorts patients by routine. In her view, the tablet fits people with a fixed morning routine, a fear of needles or frequent travel without a fridge. The pen fits shift workers, people who need coffee the moment they wake up, people who take several morning medicines and anyone who struggles to swallow tablets. Monika, who already sets phone alarms for meals and medication, fits the first group. More background on medical weight loss is collected in our fat-loss section.

Switching from the Wegovy injection to the pill

The EU product information gives a simple rule for people on the maintenance dose. Someone moving from the 2.4 mg pen to the 25 mg tablet takes the first tablet one week after the last injection. Going back, the injection follows the day after the last tablet. There is no official scheme for switching partway through the dose increases.

The same document cautions that the result of a switch "cannot easily be predicted", because absorption from the tablet varies so much more. The diabetologist interviewed by ARD was equally measured: most people who switch keep their weight, a few lose a little more, and some regain some. For Vanessa, the doctor expected a familiar problem: since the active ingredients work in the same way, the side effects may well return with the same intensity.

Both medicines are approved for use alongside a reduced-calorie diet and more physical activity, and both women in the report planned to train more to protect their muscle while losing fat. If you want structure around that part, our coaching programme provides a personal training and nutrition plan.

And what about orforglipron?

Eli Lilly's orforglipron, sold as Foundayo, is often mentioned as the next weight-loss pill. It is a small molecule rather than a peptide, so it needs no fasting or water rules and can be taken at any time of day. The FDA approved it on 1 April 2026 and the UK regulator on 10 August 2026. In the EU it was still under review in mid-September, and trade press expects a European launch in 2027. Until that changes, the Wegovy tablet is the only GLP-1 tablet that German pharmacies sell for weight loss.

Key takeaways

• The Wegovy tablet and pen contain the same drug, semaglutide, and have been sold side by side in Germany since 1 September 2026.
• At maintenance, the 25 mg tablet pack and the 2.4 mg pen pack both cost €277.60, and neither is covered by statutory health insurance for weight loss.
• In their separate trials the tablet produced 13.6% average weight loss and the pen 14.9%; the 7.2 mg pen goes further.
• How well the tablet works depends on taking it fasting, with at most 120 ml of water and a 30-minute wait afterwards.
• Switching at maintenance follows a fixed rule, but individual results are hard to predict.

This article is based on "Die Abnehmspritze gibt es jetzt als Pille" by ARD GESUND: https://www.youtube.com/watch?v=XnwyAbr_-Ng. Additional sources: pharmacist Maren Torkler (ArzneiZeit), https://www.youtube.com/watch?v=o7sEga-3d6c; the EU product information for Wegovy (EMA); OASIS 4 (Wharton et al., NEJM 2025); STEP 1 (Wilding et al., NEJM 2021).

This article is for educational purposes only. The peptides discussed are research compounds, and nothing here is medical advice. Always consult a qualified healthcare professional before making decisions about your health.